Condition: Solid Tumours · Sponsor: AstraZeneca
The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers).
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Fitzroy, Australia | Not Yet Recruiting |
| Research Site | St Albans, Australia | Not Yet Recruiting |
| Research Site | Woolloongabba, Australia | Not Yet Recruiting |
| Research Site | Batumi, Georgia | Recruiting |
| Research Site | Tbilisi, Georgia | Recruiting |
| Research Site | Tbilisi, Georgia | Recruiting |
| Research Site | Brzozów, Poland | Recruiting |
| Research Site | Koszalin, Poland | Not Yet Recruiting |
| Research Site | Lublin, Poland | Recruiting |
| Research Site | Olsztyn, Poland | Recruiting |
| Research Site | Przemyśl, Poland | Recruiting |
| Research Site | Seongnam-si, South Korea | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07391670